<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antinausea, antiemetic, and related medications used for children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antinausea, antiemetic, and related medications used for children</h1>
<div class="graphic"><div class="figure"><div class="ttl">Antinausea, antiemetic, and related medications used for children</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug class and drug</td> <td class="subtitle1">Mechanism of action</td> <td class="subtitle1">Indications</td> <td class="subtitle1">Side effects</td> </tr> <tr> <td class="subtitle2_left">Antihistamines</td> <td class="subtitle2_left">Minimal antiemetic activity</td> <td class="subtitle2_left" colspan="2"> </td> </tr> <tr> <td class="indent1">Diphenhydramine</td> <td rowspan="4">Vestibular suppression, anti-ACh effect, and H<sub>1</sub> antagonist</td> <td rowspan="4">Motion sickness.</td> <td rowspan="4">Sedation, anti-ACh effects*</td> </tr> <tr> <td class="indent1">Hydroxyzine</td> </tr> <tr> <td class="indent1">Dimenhydrinate</td> </tr> <tr> <td class="indent1">Meclizine</td> </tr> <tr> <td class="subtitle2_left">Antipsychotics</td> <td class="subtitle2_left">Mild to moderate antiemetic activity</td> <td class="subtitle2_left" colspan="2"> </td> </tr> <tr> <td class="indent1">Promethazine</td> <td>D<sub>2</sub> antagonist at CTZ and H<sub>1</sub> antagonist</td> <td rowspan="4">Chemotherapy-induced vomiting.</td> <td rowspan="4">Anti-ACh effects*, extrapyramidal reactions, QTc prolongation</td> </tr> <tr> <td class="indent1">Prochlorperazine</td> <td rowspan="2">D<sub>2</sub> antagonist at CTZ</td> </tr> <tr> <td class="indent1">Chlorpromazine</td> </tr> <tr> <td class="indent1">Olanzapine</td> <td>D<sub>2</sub> antagonist at CTZ, 5-HT<sub>6</sub> antagonist</td> </tr> <tr> <td class="subtitle2_left">Substituted benzamides</td> <td class="subtitle2_left">Moderate antiemetic activity</td> <td class="subtitle2_left" colspan="2"> </td> </tr> <tr> <td class="indent1">Metoclopramide</td> <td>D<sub>2</sub> antagonist at CTZ and 5-HT<sub>4</sub> agonist in gut</td> <td rowspan="2">GERD; gastroparesis; chemotherapy-induced vomiting.</td> <td rowspan="2">Irritability and extrapyramidal reactions</td> </tr> <tr> <td class="indent1">Trimethobenzamide</td> <td>D<sub>2</sub> antagonist at CTZ</td> </tr> <tr> <td class="indent1">Cisapride</td> <td>5-HT<sub>4</sub> agonist, ACh release in gut</td> <td>GERD; gastroparesis.</td> <td>Diarrhea, abdominal pain, headache, QT prolongation</td> </tr> <tr> <td class="subtitle2_left">Benzimidazole derivatives</td> <td class="subtitle2_left">Moderate antiemetic activity</td> <td class="subtitle2_left" colspan="2"> </td> </tr> <tr> <td class="indent1">Domperidone</td> <td>D<sub>2</sub> antagonist in gut</td> <td>Gastroparesis; chemotherapy-induced vomiting.</td> <td>Headaches; not available in the United States</td> </tr> <tr> <td class="subtitle2_left">Motilin agonist</td> <td class="subtitle2_left"> </td> <td class="subtitle2_left" colspan="2"> </td> </tr> <tr> <td class="indent1">Erythromycin</td> <td>Motilin agonist and ACh release</td> <td>Gastroparesis (eg, postinfectious).</td> <td>Nausea, diarrhea</td> </tr> <tr> <td class="subtitle2_left">5-HT<sub>3</sub> receptor antagonists</td> <td class="subtitle2_left">High antiemetic activity</td> <td class="subtitle2_left" colspan="2"> </td> </tr> <tr> <td class="indent1">Ondansetron</td> <td rowspan="5">5-HT<sub>3</sub> antagonist at CTZ and decreases vagal afferents from gut</td> <td rowspan="5"> <p>Chemotherapy- and postoperative-induced vomiting; cyclic vomiting syndrome.</p> <p>Ondansetron has also been used in the treatment of acute gastroenteritis.</p> Ondansetron comes in PO, IM, and IV formulations. All others are IV formulations only. Palonosetron has a longer half-life (40 hours).</td> <td rowspan="5">Headache, constipation</td> </tr> <tr> <td class="indent1">Granisetron</td> </tr> <tr> <td class="indent1">Tropisetron</td> </tr> <tr> <td class="indent1">Dolasetron</td> </tr> <tr> <td class="indent1">Palonosetron</td> </tr> <tr> <td class="subtitle2_left">Tachykinin receptor antagonists</td> <td class="subtitle2_left">High antiemetic activity</td> <td class="subtitle2_left" colspan="2"> </td> </tr> <tr> <td class="indent1">Aprepitant</td> <td>NK<sub>1</sub> antagonist, acts on emetic program</td> <td>Chemotherapy-induced vomiting (effect is on delayed phase, &gt;24 hours); cyclic vomiting syndrome.</td> <td>Fatigue, dizziness, diarrhea</td> </tr> <tr> <td class="subtitle2_left">Anticholinergics</td> <td class="subtitle2_left">Minimal to mild antiemetic activity</td> <td class="subtitle2_left" colspan="2"> </td> </tr> <tr> <td class="indent1">Scopolamine</td> <td>Vestibular suppression, anti-ACh</td> <td>Motion sickness.</td> <td>Sedation, anti-ACh effects*</td> </tr> <tr> <td class="subtitle2_left">Butyrophenones</td> <td class="subtitle2_left">Moderate antiemetic activity</td> <td class="subtitle2_left" colspan="2"> </td> </tr> <tr> <td class="indent1">Droperidol</td> <td>D<sub>2</sub> antagonist at CTZ; anxiolytic action and sedation</td> <td>Chemotherapy- and postoperative-induced vomiting.</td> <td>Hypotension, sedation, extrapyramidal effects</td> </tr> <tr> <td class="subtitle2_left">Benzodiazepines</td> <td class="subtitle2_left">Minimal antiemetic activity</td> <td class="subtitle2_left" colspan="2"> </td> </tr> <tr> <td class="indent1">Lorazepam</td> <td rowspan="2">Enhanced central GABA-ergic signaling; induces anxiolysis, sedation, and amnesia</td> <td rowspan="2">Adjunctive therapy (sedation) for chemotherapy-induced vomiting and cyclic vomiting syndrome<sup>¶</sup>. Diazepam may be given rectally.</td> <td rowspan="2">Sedation, respiratory depression</td> </tr> <tr> <td class="indent1">Diazepam</td> </tr> <tr> <td class="subtitle2_left">Antimigraine-abortive triptans</td> <td class="subtitle2_left" colspan="3"> </td> </tr> <tr> <td class="indent1">Sumatriptan</td> <td rowspan="4">5-HT<sub>1B1D</sub> agonist; induces cerebral vasoconstriction, relaxes gastric fundus</td> <td>Abortive approach for migraine, abdominal migraine, cyclic vomiting syndrome<sup>¶</sup>. Subcutaneous, PO, nasal and rectal formulations.</td> <td rowspan="4">Transient burning sensation in chest and neck</td> </tr> <tr> <td class="indent1">Zolmitriptan</td> <td>PO, ODT, and nasal formulations.</td> </tr> <tr> <td class="indent1">Frovatriptan</td> <td>PO formulation; longer half-life (26 hours).</td> </tr> <tr> <td class="indent1">Rizatriptan</td> <td>ODT formulation.</td> </tr> <tr> <td class="subtitle2_left">Other – NSAIDs</td> <td class="subtitle2_left" colspan="3"> </td> </tr> <tr> <td class="indent1">Ketorolac</td> <td>Cyclooxygenase inhibitor of prostaglandin synthesis</td> <td>Abortive approach for migraine, cyclic vomiting syndrome<sup>¶</sup>.</td> <td>Gastrointestinal bleeding</td> </tr> <tr> <td class="subtitle2_left">Antimigraine – prophylactic medication</td> <td class="subtitle2_left" colspan="3"> </td> </tr> <tr> <td class="indent1">Cyproheptadine</td> <td>H<sub>1</sub> antagonist and 5-HT<sub>2</sub> antagonist</td> <td rowspan="2">Prevention of migraine, abdominal migraine, cyclic vomiting syndrome.</td> <td>Sedation, anti-ACh effects*, weight gain due to appetite stimulation</td> </tr> <tr> <td class="indent1">Pizotifen, pizotyline</td> <td>5-HT<sub>2</sub> antagonist</td> <td>Not available in the United States</td> </tr> <tr> <td class="indent1">Propranolol</td> <td>β<sub>1</sub>, β<sub>2</sub> adrenergic antagonist</td> <td>Prevention of abdominal migraine, cyclic vomiting syndrome.</td> <td>Hypotension, bradycardia, fatigability; monitor pulse</td> </tr> <tr> <td class="indent1">Amitriptyline, nortriptyline</td> <td>5-HT<sub>2</sub> antagonist, increases synaptic norepinephrine</td> <td>Prevention of migraine, abdominal migraine, cyclic vomiting syndrome<sup>¶</sup>.</td> <td>Sedation, anti-ACh effects*, QTc prolongation</td> </tr> <tr> <td class="subtitle2_left">Corticosteroids</td> <td class="subtitle2_left" colspan="3"> </td> </tr> <tr> <td class="indent1">Dexamethasone</td> <td>Unknown</td> <td>Adjunctive therapy for chemotherapy- and postoperative-induced vomiting.</td> <td>Adrenal suppression</td> </tr> <tr> <td class="subtitle2_left">Cannabinoids</td> <td class="subtitle2_left" colspan="3"> </td> </tr> <tr> <td class="indent1">Dronabinol</td> <td rowspan="2">Acts on CB1R receptors on vagus</td> <td rowspan="2">Chemotherapy-induced vomiting.</td> <td rowspan="2">Disorientation, vertigo, hallucinations</td> </tr> <tr> <td class="indent1">Nabilone</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>ACh: acetylcholine; H: histamine; D: dopamine; CTZ: chemoreceptor trigger zone; 5-HT: 5-hydroxytryptamine (serotonin); GERD: gastroesophageal reflux disease; PO: orally; IM: intramuscularly; IV: intravenously; NK: neurokinin; GABA: gamma aminobutyric acid; ODT: orally dissolving tablet; NSAID: nonsteroidal antiinflammatory drug; CB1R: cannabinoid receptor 1.</p>
<p>* Anticholinergic effects include blurred vision, dry mouth, hypotension, palpitations, and urinary retention.</p>
¶ Pharmacotherapy for cyclic vomiting syndrome may be preventive, supportive, or abortive, depending on the patient's characteristics. For detailed guidance, refer to UpToDate content and tables on cyclic vomiting syndrome.</div><div class="graphic_reference">Adapted from: B U K. Li, "Vomiting and pyloric stenosis." In Walker's Pediatric Gastrointestinal Disease, 5th Edition. Kleinman RE, Sanderson IR, Goulet O, Sherman PM, Mieli-Vergani G, and Shneider BL, Eds. B.C. Decker Inc. Hamilton, Ontario, 2008. Used with permission from People's Medical Publishing House—USA (PMPH-USA), Shelton, CT.</div><div id="graphicVersion">Graphic 100351 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
